Virulence of Newcastle disease virus: what is known so far?
about
High pathogenicity and low genetic evolution of avian paramyxovirus type I (Newcastle disease virus) isolated from live bird markets in Uganda.The deletion of an extra six nucleotides in the 5' -untranslated region of the nucleoprotein gene of Newcastle disease virus NA-1 decreases virulence.New avian paramyxoviruses type I strains identified in Africa provide new outcomes for phylogeny reconstruction and genotype classification.Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.The M, F and HN genes of genotype VIId Newcastle disease virus are associated with the severe pathological changes in the spleen of chickens.Evolution of Newcastle Disease Virus Quasispecies Diversity and Enhanced Virulence after Passage through Chicken Air Sacs.Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.Prevalence of avian paramyxovirus type 1 in Mallards during autumn migration in the western Baltic Sea region.Contribution of HN protein length diversity to Newcastle disease virus virulence, replication and biological activities.Virus interference between H7N2 low pathogenic avian influenza virus and lentogenic Newcastle disease virus in experimental co-infections in chickens and turkeys.Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.The long view: a selective review of 40 years of Newcastle disease research.Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme.Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.The therapeutic effect of death: Newcastle disease virus and its antitumor potential.Molecular evolution and epidemiological links study of Newcastle disease virus isolates from 1995 to 2016 in Iran.Simultaneous mutation of G275A and P276A in the matrix protein of Newcastle disease virus decreases virus replication and budding.Detection of Inter-Lineage Natural Recombination in Avian Paramyxovirus Serotype 1 Using Simplified Deep Sequencing Platform.Immunogenicity and protection efficacy evaluation of avian paramyxovirus serotype-1 (APMV-1) isolates in experimentally infected chickens.Intravenously injected Newcastle disease virus in non-human primates is safe to use for oncolytic virotherapy.Detection and molecular characterization of Newcastle disease virus in peafowl (Pavo cristatus) in Haryana State, India.Newcastle disease virus fusion and haemagglutinin-neuraminidase proteins contribute to its macrophage host rangeImproved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes.Different Origins of Newcastle Disease Virus Hemagglutinin-Neuraminidase Protein Modulate the Replication Efficiency and Pathogenicity of the Virus.Characterization of a novel VIIl sub-genotype of Newcastle disease virus circulating in Iran.Stimulus-responsive viral vectors for controlled delivery of therapeutics.Genetic, antigenic, and pathogenic characteristics of Newcastle disease viruses isolated from geese in China.An Australian Newcastle Disease Virus With a Virulent Fusion Protein Cleavage Site Produces Minimal Pathogenicity in Chickens.Novel Mechanisms Revealed in the Trachea Transcriptome of Resistant and Susceptible Chicken Lines following Infection with Newcastle Disease Virus.Roles of the Polymerase-Associated Protein Genes in Newcastle Disease Virus Virulence.Pathogenesis of Renal Lesions in Chickens After Experimental Infection With 9a5b Newcastle Disease Virus Mutant Isolate.Synthesis and Antiviral Activity of Novel Phosphorylated Derivatives of Didanosine Against Newcastle Disease Virus in Chicken.Neuropathogenic Capacity of Lentogenic, Mesogenic, and Velogenic Newcastle Disease Virus Strains in Day-Old Chickens.Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.Two mutations in the HR2 region of Newcastle disease virus fusion protein with a cleavage motif "RRQRRL" are critical for fusogenic activityGenetic characterization and pathogenicity assessment of Newcastle disease virus isolated from wild peacock.Pigeon paramyxovirus type 1 variants with polybasic F protein cleavage site but strikingly different pathogenicity.Characterization of genotype IX Newcastle disease virus strains isolated from wild birds in the northern Qinling Mountains, China.Effects of the HN gene C-terminal extensions on the Newcastle disease virus virulence.
P2860
Q34308905-294FFD36-C608-4789-B32A-5338EB88B869Q34979013-4D2E3ECD-7AED-4580-B203-055F829DEC2AQ35034669-267DACD6-78BF-44FD-9B83-064C1EEAB5F9Q35861936-7FC0CAF3-91AE-4A88-99A0-21B455342601Q36023225-9C78EFBB-326A-4C5D-B22B-C400F3B015F7Q36524021-D1BA1DFC-C665-409A-AFF5-8A8466D23A82Q37069810-7F404D91-0C95-4A9B-8BD0-024860536AC3Q37133496-5EB69783-6C59-4299-8D78-468EDA39CDE0Q37357288-0653C813-45EC-45AB-8505-F17F5696090CQ37408457-898840F7-73E1-4B76-9B15-E7BA47FDB8A7Q37473905-AA36E311-143D-4F9F-AD51-2E5E0A65B1CBQ37990940-C7388DCA-A782-4A80-BE18-967EB54A4407Q38029720-CC96C7FB-7D80-42CA-B82F-5DF194512B1EQ38253056-76D0D1D4-2BF1-4F47-87A2-7B1916EBC251Q38264652-3E19B631-CDBE-443A-A3F1-B7EE7607012DQ38556725-BE428003-609F-447E-9F8D-25DB6E6BE9BBQ38597117-1B1461FD-63AF-45D8-A4B1-A7CD77F9838BQ38747892-D0161F58-C154-4743-BF1F-B424A6B96094Q38783141-CADC69C4-BCD1-49F8-B520-D3995593F6AFQ38851002-7625F551-7D06-41F7-9E85-C0BBFB6435E8Q38953230-1692D9CC-5731-408F-BA01-A371CCF342CDQ39034271-AA641949-1A6F-460A-9FDA-6B494E68FF02Q39191423-A13586E8-3E86-4244-B26A-0CEBFBF2F4E1Q39532024-22E580ED-BCE2-4507-A0A3-9A42979BA329Q40054763-6A3ABA37-9520-49EC-8E51-BC058C1CA801Q40057159-3CDABE61-26F3-43B7-90AC-0E547BC16757Q40069936-3A9691BF-BCBD-4A19-A8F5-9CEBCAA5C838Q40184091-C40C29C7-80B8-4FA3-8764-7229A888B6B4Q40205398-3076E4D5-04AB-4630-A5B3-A7AC2B9073A8Q40279398-A96E489A-0850-4EA5-84B9-B3BCF90FA60FQ40326460-0F6DC5AC-DEB1-4CEF-A9AE-D04001BF2835Q40627911-2E3B922C-FF80-435F-9458-60EB96172740Q40693874-6180657F-1BF8-410A-995A-440B5FFD16B1Q40987107-170B1045-44EA-4791-ACEC-601220E013E4Q41456207-C32A6A6F-B59E-447E-B888-902E4D76A971Q41930545-DE972C8C-BD21-4067-A34C-24C96876E80CQ42185749-DC72CDA0-E591-4DA7-99CB-B035E0B26445Q42187237-4277B9C7-309B-42E1-A417-7A4DAC9C1918Q42265412-13CAD8A8-41D9-4166-A6C5-1F5ADDB5EC45Q42269591-C0A9AED0-2F89-4C2E-885C-864870FD3EBA
P2860
Virulence of Newcastle disease virus: what is known so far?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Virulence of Newcastle disease virus: what is known so far?
@en
Virulence of Newcastle disease virus: what is known so far?
@nl
type
label
Virulence of Newcastle disease virus: what is known so far?
@en
Virulence of Newcastle disease virus: what is known so far?
@nl
prefLabel
Virulence of Newcastle disease virus: what is known so far?
@en
Virulence of Newcastle disease virus: what is known so far?
@nl
P2093
P2860
P356
P1433
P1476
Virulence of Newcastle disease virus: what is known so far?
@en
P2093
Ben P H Peeters
Jos C F M Dortmans
P2860
P2888
P356
10.1186/1297-9716-42-122
P577
2011-12-23T00:00:00Z
P5875
P6179
1049997133